Operating Income (Loss) of BridgeBio Oncology Therapeutics, Inc. from 31 Dec 2023 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
BridgeBio Oncology Therapeutics, Inc. quarterly and annual Operating Income (Loss) in USD history and change rate from 31 Dec 2023 to 31 Dec 2025.
  • BridgeBio Oncology Therapeutics, Inc. Operating Income (Loss) for the quarter ending 31 Dec 2025 was $43,408,000, a 98% decline year-over-year.
  • BridgeBio Oncology Therapeutics, Inc. Operating Income (Loss) for the twelve months ending 31 Dec 2025 was $96,132,034, a 130% decline year-over-year.
  • BridgeBio Oncology Therapeutics, Inc. annual Operating Income (Loss) for 2025 was $145,819,000, a 80% decline from 2024.
  • BridgeBio Oncology Therapeutics, Inc. annual Operating Income (Loss) for 2024 was $80,863,000, a 193853% decline from 2023.
Source SEC data
View on sec.gov
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

BridgeBio Oncology Therapeutics, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $96,132,034 $43,408,000 -$21,529,000 -98% 01 Oct 2025 31 Dec 2025 8-K 05 Mar 2026
Q3 2025 $74,603,034 $49,181,000 -$29,517,000 -150% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $45,086,034 $1,121,848 -$969,505 -636% 01 Apr 2025 30 Jun 2025 10-Q 01 Aug 2025 2025 Q2
Q1 2025 $44,116,529 $2,421,186 -$2,354,485 -3530% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $41,762,044 $21,879,000 01 Oct 2024 31 Dec 2024 8-K 05 Mar 2026
Q3 2024 $19,664,000 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $152,343 01 Apr 2024 30 Jun 2024 10-Q 01 Aug 2025 2025 Q2
Q1 2024 $66,701 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1

BridgeBio Oncology Therapeutics, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $145,819,000 -$64,956,000 -80% 01 Jan 2025 31 Dec 2025 10-K 05 Mar 2026 2025 FY
2024 $80,863,000 -$80,821,308 -193853% 01 Jan 2024 31 Dec 2024 10-K 05 Mar 2026 2025 FY
2023 $41,692 01 Jan 2023 31 Dec 2023 10-K 11 Mar 2025 2024 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.